Inventor · disambiguated record
Patrick Hagner
Also filed as: HAGNER PATRICK · HAGNER PATRICK R
4 granted patents·10 pending applications·8 citations·filing 2014–2022
65Inventor score
Top patents by PatentIndex Score
14 records- 0189US10996215B2Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2018·Granted May 4, 2021·5 cites·21 claims
- 0283US10689708B2Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugsCELGENE CORP·Filed 2016·Granted Jun 23, 2020·3 cites·11 claims
- 0367US2022003749A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2021·Application pending·0 cites
- 0457US2024228667A9Methods for Treating Multiple MyelomaCELGENE CORP·Filed 2022·Application pending·0 cites
- 0555US9956226B2Methods and compounds for the inhibition of cellular proliferationHARVARD COLLEGE·Filed 2014·Granted May 1, 2018·0 cites·3 claims
- 0654US2016313300A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2014·Application pending·0 cites
- 0752US2021102257A1Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor to responsiveness to drugsCELGENE CORP·Filed 2020·Application pending·0 cites
- 0847US2023364230A1Combination therapy for cancerENGMAB SARL·Filed 2021·Application pending·0 cites
- 0945US10159675B2Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dioneCELGENE CORP·Filed 2016·Granted Dec 25, 2018·0 cites·22 claims
- 1044US2023023070A1Therapy for the Treatment of CancerCELEGENE CORP·Filed 2020·Application pending·0 cites
- 1144US2017242014A1Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2014·Application pending·0 cites
- 1241US2017157103A1Methods of treating diffuse large b-cell lymphoma using 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dioneCELGENE CORP·Filed 2016·Application pending·0 cites
- 1336US2018231561A1Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2016·Application pending·0 cites
- 1436US2017038387A1Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapiesCELGENE CORP·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Patrick Hagner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →